Impact of interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer patients

Table 6 Kaplan-Meier survival estimates

Variable	No. of cases	DFS P value	OS P value
Sex (n, %)		0.668	0.448
Male	160 (69.3)
Female	71 (30.7)
Age (year)		0.518	0.688
< 60	111 (48.1)
≥ 60	120 (51.9)
ASA (n, %)		0.691	0.658
1	7 (3)
2	178 (77)
3	46 (19.9)
BMI (kg/m2)		0.759	0.587
< 25	149 (64.5)
≥ 25	82 (35.5)
Interval time, w (%)		0.002	0.259
≤ 9 wk	139 (60.2)
> 9 wk	92 (39.8)
cT, n (%)		0.343	0.483
2	2 (0.9)
3	180 (77.9)
4	49 (21.2)
cN, n (%)		0.059	0.084
0	62 (26.8)
1	119 (51.5)
2	50 (21.6)
ypT, n (%)		< 0.001	0.001
0	40 (17.3)
1	5 (2.2)
2	48 (20.8)
3	121 (52.4)
4	17 (7.4)
ypN, n (%)		0.001	0.185
0	128 (55.4)
1	74 (32)
2	29 (12.6)
Surgical procedure		0.109	0.464
Miles (n, %)	100 (43.3)
Dixon (n, %)	113 (48.9)
Hartmann (n, %)	18 (7.8)
Postoperative complications, n (%)		0.265	0.043
Yes	12 (5.2)
No	219 (94.8)
Degree of differentiation, n (%)		0.094	0.183
Low and low-moderate grades	32 (13.9)
Moderate, moderate-high, and high grades	193 (83.5)
Signet-ring and mucinous adenocarcinoma	6 (2.6)
Preoperative concurrent chemotherapy regimen, n (%)		0.357	0.533
Capecitabine + oxaliplatin	71 (30.7)
Capecitabine oral	145 (62.8)
Oxaliplatin union	15 (6.5)

BMI: Body mass index; ASA: American Society of Anesthesiologists; DFS: Disease-free survival; OS: Overall survival.